Replies to post #49315 on Biotech Values

[gophie]

CLSC.ob & RIGL

http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle&ID=791646&highlight=

Rigel ultimately dropped R112 for allergic rhinitis. At least their trial design had one arm using Beconase AQ, thereby leaving no doubt that R112 did not work well because of the short half life.

By not taking the blame on poor trial design, Cobalis is blaming Mother Nature.

[exwannabe]

Well, CLSC did report N.

I know the trial failed, but they might have found some remotely positive number to put in a PR after sieveing the unblinded data for 3 months.

Even the actuall placebo numbers (so one could decide if the explanation was BS or not) would have been usefull.

Perhapse the trial failed somewhat worse than the PR lets on?